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Gerard Duru2, Lauriane Depaepe4, Brigitte Balme4 and Stephane Dalle1,2,3
Second primary melanomas (SPMs) induced by vemurafenib have been recently described. The aim of this study
was to define the dermoscopical signs of melanoma in this context. Patients underwent a total body examination
before receiving vemurafenib. Each single melanocytic lesion was registered before therapy by digital dermo-
scopy (DD), and then repeated monthly until therapy disruption. Forty-two patients were included, the mean
duration of follow-up was 6.7 months, and a mean number of 51 lesions per patients were captured and followed.
A total number of 2,155 lesions were recorded, of which 56.1% presented at least one change during the study.
More common changes concerned the color of the lesions (up to 15%) and appearance or disappearance of
globules (14.6%). Thirty-six of the melanocytic lesions were surgically excised, 21 were classified as a nevus, 1 was
a lentigo, and 14 as a second new primary melanoma (occurring in 21% of our patients). DD allowed us to excise
only 36/2,155 (1.6%) of the lesions and permitted us to detect 14 SPM in the 42 patients with a highly efficient
malignant/benign ratio of 63.6%. Although vemurafenib is now tested in an adjuvant setting DD should be
systematically used in order to accurately detect SPM and reduce the number of unnecessary excisions.
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INTRODUCTION
Vemurafenib was approved in 2011 for the treatment of
metastatic or unresectable melanoma ([No authors listed],
2011; da Rocha Dias et al., 2013), as a selective inhibitor of
the V600E mutated BRAF kinase. This activating mutation of
the gene encoding for BRAF is present in approximately 50%
of human melanomas (Davies et al., 2002; Curtin et al., 2005),
leading to over activity in the mitogen-activated protein kinase
pathway and uncontrolled cell growth. It occurs in 92%
within the kinase domain, with a substitution of valine for
glutamate at codon 600 (Takata and Saida, 2006). In
previously published clinical trials, 6 months overall survival
was estimated at 84% in the vemurafenib group and 64% in
the dacarbazine group, response rates being 48% and 5%,
respectively (Chapman et al., 2011). Common observed
adverse events included arthralgia, fatigue, nausea, diarrhea,
and unspecific skin rash. These adverse effects require dose
modifications in 38% of the patients (Anforth et al., 2012;
Boyd et al., 2012; Chu et al., 2012; Dummer et al., 2012;
Huang et al., 2012; Hwa et al., 2012; Zimmer et al., 2012b;
Kim et al., 2013; Lacouture et al., 2013; Villani et al., 2013).
Squamous cell carcinomas, usually well differentiated, are
observed in 26% of the patients under treatment (Sosman
et al., 2012). Changes in pre-existing pigmented lesions under
vemurafenib and dabrafenib were more recently reported. The
first reports indicated either the regression or darkening of nevi
(Chu et al., 2012; Haenssle et al., 2012) or the appearance of
new nevi (Ma et al., 2012; Schmitt et al., 2013). Acquired
atypical dermoscopic features within pre-existing nevi
were subsequently reported (Gerami et al., 2012; Haenssle
et al., 2012). Along with others, we mentioned the occurrence
of second primary melanomas (SPMs) under vemurafenib
(Dalle et al., 2011; Zimmer et al., 2012a; Debarbieux et al.,
2013) corresponding either to newly developed pigmented
lesions, or rapidly changing pre-existing melanocytic
lesions. To the best of our knowledge, a prospective follow-
up of all nevi modifications on various patients under
BRAF blockers has never been published before. We report
herein a longitudinal study of dermoscopic changes occurring
on the pigmented lesions of 42 patients receiving vemurafenib
for advanced melanoma. Our aim was to better understand
the impact of vemurafenib on pre-existing melanocytic
lesions.
RESULTS
Forty-two unselected consecutive patients were prospectively
included in this study, 13 women (31%) and 29 men (69%),
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whose mean age was 60.5 (range from 29 to 87 years). The
mean duration of follow-up was 6.7 months (1–19 months),
and the mean number of followed up pigmented lesions per
patient was 51.3, ranging from 7 to 143 (Table 1). A total
number of 2,155 lesions were initially recorded. According to
the patient outcome, eventual treatment discontinuation, and
lost-from-follow-up-patient’s missing data (the main reason for
these was the poor general condition of progressing patients
ethically incompatible with the relatively long systematic skin
examination), the total number of captured lesions decreased
over the time. After 1 month, 1,791 were recorded, decreasing
to 791 lesions after 6 months and 381 lesions after 12 months.
Most of the changes were observed within the first 5 months of
treatment (from 26.1 to 30%), and with a peak of frequency
of 49.9% during the second month (Figure 1). Overall, 56.1%
of the lesions were modified during the follow-up.
Changes related to the color of the entire lesion were most
commonly noticed. These changes occurred early with up to
15% modifications during the first 2 months (Figure 2). It is
noteworthy that high percentages of modification within month
16 are probably related to a bias of rank size (o80 pigmented
lesions and five patients were still under follow-up at month
16). Modifications related to the globular structures (appear-
ance of new globules or disappearance of pre-existing glo-
bules) were seen in 14.6% of the lesions and more common
between months 3 and 6. Appearance of new globules was
observed in 11.5% of the melanocytic lesions, whereas
disappearance was only seen in 5.3%. Besides the color
changes affecting the entire lesion, focal changes, either hyper
or hypo-pigmentation (7.3%), and onset of dark structureless
areas (5.1%) were frequently observed. Increase in diameter
(4.6%) and changes concerning the dermoscopic network
(4.4%) were less frequent (Supplementary Figures S1 and S2
online). The onset of superficial hyperkeratosis (1.46% of the
pigmented lesions), geometrical changes (asymmetry), and
vascular changes were uncommon and observed in 0.23 and
0.15% of melanocytic lesions, respectively. Rates of changes
on the 10 dermatologic criteria are summarized in Figure 3.
Aside from the global analysis considering every single
pigmented lesion as the statistical object, inter individual
differences were studied at the patient level. Accordingly,
frequency of change in one given patient varied from 8.2 to
93.8%. We therefore identified three groups of patients, those
who presented few changes of their pigmented lesions (group 1,
ranging from 0 to 39.9% of changing lesions at least on one
dermoscopical criterion, n¼ 11, 26.2% of patients, average
change rate of 22.7%), those who presented rates of changes
from 40 to 59.9% (group 2, n¼12, 28.6% of patients, mean
change rate of 46.9%), and those who showed a high frequency
of pigmented lesion modifications (group 3, 60% or more,
n¼ 19, 45.2% of patients, mean change rate of 78.3%;
Figure 4). Patients bearing an atypical nevus syndrome were at
higher risk of change and represented 25% of patients in group 2
and 21.1% in group 3, whereas they were absent in group 1
(Supplementary Table S1 online). On the other hand, past history
of intense sun exposure was less associated with modifications
under treatment (60% of patients in group 1 reported chronic sun
exposure, whereas 61.1% of patients in group 3 did not).
Thirty-six (1.7%) of the melanocytic lesions were surgically
removed. After independent pathology examination by at least
two of us (BB and LD); 21 were classified as melanocytic nevi
(of which 9 were dysplastic), 1 was a lentigo, and 14 SPMs
(average thickness of 0.27 mm, ranging from in situ to
0.85 mm). BRAF genotypic status, when determined, was
always of the wild type. Fourteen SPMs were excised in 9/
42 patients (21%). The mean delay between the initiation of
therapy and SPM diagnosis was at 4.1 months. Pathology
reports are mentioned in Table 1. Studying the dermoscopic
features between excised atypical/activated nevi and melano-
mas (Table 2), we were not able to differentiate significant
differences regarding homogeneous darkening of color,
decreasing of size, pattern change, onset of dermoscopic signs
of regression, keratosis, or new vessels. This was expected as
all lesions were excised because of a high suspicion of
melanoma and, considering this, our false-positive cases (22/
36) and our malignant/benign ratio (63.6%) were very com-
parable to previously published data on digital dermoscopy
(DD) performances in referral pigmented lesion clinics
(Lacouture et al., 2013).
Comparing the group of excised lesions and the group of
modified-but-non-excised ones, no statistical difference was
observed according to the number of changes occurring
during the period of follow-up (mean number of changes of
3.1 and 2.9, respectively, P¼0.28). However, during the first
month, appearance of localized changes in pigmentation,
structureless dark areas, or globules were more frequently
observed in the excised lesions than in the only modified ones
(P¼ 0.006, 0.001, and 0.041, respectively). Changes in black
structureless areas, in network, and in diameter were the
dermoscopic features that led more frequently to excision
during the second month (P¼0.049, 0.029, and 0.002,
respectively), whereas localized changes in pigmentation
and in diameter were the most decisive criteria within the
third month (P¼0.038 and 0.035). No difference was
observed between these two groups according to changes in
global color, hyperkeratosis, vessels, dermoscopic pattern, or
symmetry, or for any given criteria after the third month.
Considering the body areas for melanomas and modified
nevi, occurrence 86% and 90%, respectively, occurred on
skin areas protected from chronic exposure, whereas 14% and
10% occur on chronically sun-exposed skin (Table 1).
DISCUSSION
Modifications in pigmented lesions have been reported less
frequently than the onset of squamous cell carcinomas under
blockers of the mitogen-activated protein kinase pathway,
including the non-selective BRAF inhibitor sorafenib
(Bennani-Lahlou et al., 2008; Kong et al., 2008) and the
selective BRAF inhibitor vemurafenib (Chu et al., 2012). This
question became, however, crucial with the observance of
SPMs in patients treated by vemurafenib (Dalle et al., 2011;
Zimmer et al., 2012a; Debarbieux et al., 2013), raising the
question on the long-term impact of BRAF inhibitors on pre-
malignant or dormant malignant pigmented lesions. Although
several hypotheses were suggested regarding the mechanisms
of primary and secondary resistance to vemurafenib, it has
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Table 1. Main characteristics of dermoscopic changes, excised lesions, and pathology reports observed in 42 patients
Patient
number
Gender
(M/F) Age
Total of
pigmented
lesions
followed
Percentage of
pigmented lesions
significant
change
Number
excised
lesions
Interval from
treatment start to
lesion excision
Location
of excised
lesion Pathology report
Molecular
BRAF
status
1 M 53 16 93.8 0
2 M 67 35 80.0 0
3 M 68 64 81.3 1 8 Months Back Lentigo
4 F 58 39 17.9 0
5 M 70 12 41.7 0
6 F 49 30 73.3 2 5 Months
11 Months
Forearm
Knee
Compound nevi
In situ melanoma
NA
NA
7 M 46 37 24.3 0
8 F 49 40 50.0 0
9 M 64 9 22.2 0
10 M 59 56 23.2 1
11 F 42 66 62.1 0 6 Months Breast Compound nevi NA
12 M 29 77 89.6 0
13 F 48 132 47.7 0
14 F 61 32 25.0 1 6 Months Calf Compound nevi NA
15 M 80 73 8.2 0
16 F 79 9 66.7 0
17 M 77 20 85.0 0
18 M 68 22 77.3 1 1 Month Thigh Compound nevi NA
19 M 70 25 24.0 0
20 M 65 63 54.0 4 3 Months
3 Months
1 Month
7 Months
Back
Back
Back
Buttock
SSM melanoma
0.13 mm
SSM melanoma 0.3mm
Atypical nevi
Compound nevi
Wild type
Wild type
NA
NA
21 M 40 42 78.6 2 2 Months
4 Months
Torso
Thigh
SSM melanoma 0.5mm
Atypical nevi
NA
NA
22 M 80 77 76.6 0
23 F 63 64 82.8 3 3 Months
3 Months
3 Months
Thigh
Arm
Shoulder
Nevi
Compound nevi
Compound nevi
NA
Wild type
NA
24 M 46 52 67.3 4 3 Months
3 Months
3 Months
4 Months
Back
Back
Torso
Back
SSM melanoma 0.3mm
SSM melanoma 0.4mm
SSM melanoma
0.15 mm
In situ melanoma
Wild type
Wild type
Wild type
NA
25 M 45 34 79.4 3 4 Months
4 Months
4 Months
Abdomen
Thigh
Thigh
Atypical nevi
Atypical nevi
SSM melanoma 0.3mm
Wild type
Wild type
Wild type
26 M 63 103 25.2 0
27 F 87 46 54.3 0
28 M 67 31 80.6 0
29 M 68 60 40.0 1 5 Months Breast SSM melanoma
0.45 mm
Wild type
30 M 58 77 54.5 1 2 Months Shoulder Compound nevi NA
31 M 68 38 26.3 3 2 Months
1 Month
1 Month
Shoulder
Back
Back
Junctional nevi
Compound nevi
Atypical nevi
NA
NA
NA
Table 1 continued on following page
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been shown that melanocytic BRAF-V600E lesions may
acquire resistance to vemurafenib (Nazarian et al., 2010;
Basile et al., 2012; Sullivan and Flaherty, 2013). Little is
known about the effect of selective V600E BRAF inhibition
on wild-type BRAF-bearing nevi (Gibney et al., 2013).
It has, however, been shown in vitro that the growth of
BRAF wild-type melanocytes can be enhanced by their
exposure to V600E BRAF blockers through a MEK (mitogen-
activated protein kinase/extracellular signal–regulated kinase)/
extracellular signal–regulated kinase paradoxical activation
(Hatzivassiliou et al., 2010; Poulikakos et al., 2010).
Gerami et al. (2012) reported for the first time the case of a
patient with marked dermoscopic changes in some of his nevi
after 5 weeks under vemurafenib, and they described the
nature of these changes but number and evolution of the
examined lesions were not detailed. Haenssle et al. (2012)
also reported a case of a Fitzpatrick’s skin type II patient under
vemurafenib and detailed the dermoscopic dynamic changes
occurring after 3 months, but only in a small number of
pigmented lesions (Bowling et al., 2007).
The efficiency of DD has been assessed for the detection of
early melanomas among atypical melanocytic lesions, by a
short-term (2–3 months) monitoring, with a specificity of 84%
(Altamura et al., 2008; Menzies et al., 2011). Indeed, the
technique permits the early detection of melanomas with low
Breslow’s thickness, when showing any dermoscopical
change after 3 months (change in the number in milia-like
cysts and overall tanning of the lesions proportional to the
tanning of the surrounding skin excepted) in pigmented lesions
initially lacking dermoscopic evidence of malignancy. A
changing lesion should be surgically removed for histopa-
thological examination. This technique undoubtly permits to
minimize the number of unnecessarily excised benign lesions
when compared with clinical naked-eye follow-up or even to
the use of optical dermoscopy alone (Tromme et al., 2012;
Salerni et al., 2013). Under vemurafenib, the situation is
markedly different, as 450% of the captured lesions are
showing substantial changes induced by the drug. Moreover,
these changes occur very rapidly after the initiation of the
treatment: at the third month, 32.6% of the followed lesions
presented at least one dermoscopical change. In this context,
efficient criteria to adequately decide whether or not a given
lesion should be removed were lacking. In this study, the
clinicians made their decision based on their clinical
Table 1. (Continued )
Patient
number
Gender
(M/F) Age
Total of
pigmented
lesions
followed
Percentage of
pigmented lesions
significant
change
Number
excised
lesions
Interval from
treatment start to
lesion excision
Location
of excised
lesion Pathology report
Molecular
BRAF
status
32 M 68 109 87.2 0
33 M 70 33 48.5 1 4 Months Back SSM melanoma
0.85 mm
NA
34 F 73 7 42.9 0
35 M 65 143 78.3 4 5 Months
2 Months
8 Months
2 Months
Torso
Torso
Arm
Back
SSM melanoma 0.3mm
Compound nevi
Compound nevi
Atypical nevi
NA
NA
NA
NA
36 M 40 35 31.4 0
37 F 74 11 45.5 0
38 M 31 59 22.0 0
39 M 72 49 67.3 0
40 M 38 70 80.0 1 1 Month Back Atypical nevi NA
41 F 82 62 43.5 3 4 Months
4 Months
4 Months
Back
Calf
Calf
Compound nevi
In situ melanoma
SSM melanoma
0.13 mm
NA
NA
NA
42 F 51 96 40.6 0
Abbreviations: F, female; M, male; NA, not applicable; SSM, superficial spread melanoma.
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Figure 1. Percentage of dermoscopic changes observed during follow-up.
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experience but had to apply a much higher DD-based
decision threshold than in usual management of pigmented
lesions even in very high-risk patients regularly followed in
pigmented lesions clinics (patients with genetic predisposition
to melanoma, patient bearing an atypical mole syndrome,
or patient with personal or family history of multiple
melanomas). However, comparing the excised lesions and
the modified-but-not-excised ones, we could demonstrate that
the number of observed changes within one given lesion was
not significant and that only some qualitative changes could
be taken into account and this, only during the three first
months of follow-up. The dermoscopic criteria, which led
most frequently to surgical removal during the first 3 months
of treatment, were localized changes in local pigmentation
(also known as onset of ‘dermoscopic islands’), appearance of
dark structureless areas, changes in network, or in diameter.
Changes in globules were discriminatory only during the first
month.
On the basis of our study and previously reported observa-
tions, standard recommendations regarding DD such as the
compulsory excision of any changing lesion after 3 months
and the time schedule of the control visits should not be
applied to patients under BRAF modifiers. We suggest a
monthly examination by DD during at least the first 3 months
followed by a check every 3 months. Surgical excision of one
melanocytic lesion should be envisaged if observed modifica-
tions are localized pigmentation change, appearance of
structureless areas, and network or diameter changes during
Figure 2. Dermoscopic features during follow-up of three melanocytic lesions in three patients: patient 12 (first line), patient 21 (second line), and patient
32 (third line).
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the first 3 months. On the other hand, in BRAF-blocker treated
patients commonly observed DD changes occurring in
globules or in overall color, or more unusual DD
changes occurring in surface hyperkeratosis, vessel pattern,
or symmetry should not systematically lead to the surgical
excision of the lesion although they could be observed in
a short follow-up.
We found in our cohort of patients under vemurafenib a risk
of 21% of a subsequent new primary melanoma, with mean
time between start of treatment and diagnosis of 4.1 months. It
is well established that patients previously diagnosed with
melanoma are at higher risk of developing other new primary
melanomas. This life-time risk is generally estimated from
1.9% (Bower et al., 2010) to 10.8% (Murali et al., 2012). For
some authors, this risk is highest during the first year after
surgical treatment of the primary skin lesion, from 4.1% (Hwa
et al., 2012) to 6% (Ferrone et al., 2005), and remains high up
to 20 years after the first diagnosis (de Giorgi et al., 2012).
Compared with these data, SPMs under BRAF inhibitors are
likely to be much more frequent and of much earlier onset. It
can be suggested that these melanomas were biologically
present yet dormant, and, moreover, clinically undetectable
before the initiation of therapy, and therefore only revealed by
the wild-type BRAF paradoxical activation by specific V600E
BRAF blockers, then picked up by repeated follow-up. We
previously partially addressed this issue with the help of
reflectance confocal microscopy, a non-invasive technique
that allows a quasi-histopathological assessment of the lesions
without surgical excision (Debarbieux et al., 2013). In this
work, several pigmented lesions were randomly selected in a
small group of patients and examined by reflectance confocal
microscopy before treatment and re-examined in comparison
after 3 months under vemurafenib. Although all of the lesions
were initially considered as benign using standard reflectance
confocal microscopy rules for the diagnosis of pigmented
lesions, we observed in some of them the occurrence of
unifocal or multifocal areas of marked atypia demonstrating
the direct impact of vemurafenib. All significantly changed
lesions were removed and four additional SPMs were
diagnosed. Ongoing additional biomolecular studies may
now help to specify whether the pre-existing melanocytic
lesions are incognito dormant melanomas or atypical nevi.
We cannot exclude that some melanomas were missed in this
study because of the large number on changing lesions left
unexcised. This represents a potential misclassification bias;
however, systematic monthly examination of all patients
during their treatment did not permit to find additional late
changes indicating a potentially missed early melanoma
during the first months of treatment.
In conclusion, we analyzed 2,155 pigmented lesions in 42
patients under vemurafenib and showed that dermoscopic
changes occur in up to 49.9% during the second month,
mainly as homogeneous increase of pigmentation and appear-
ance of new globules. These changes occur in the majority in
the first five months after treatment initiation. We also
demonstrate that the rate of such modifications is highly
variable among individuals; it is noteworthy that in up to
45.2% of the patients included 460% of their pigmented
lesions were ultimately modified under BRAF blockers. Our
findings also highlight the need of very close dermatologic
management of these patients, using adequate tools including
optical dermoscopy but also DD and maybe reflectance
confocal microscopy. The perspective of the use of an anti-
BRAF treatment, in an adjuvant setting in patients with
a longer life expectancy, even in case of non initially
cutaneous malignancies, is another reason to recommend
highly specialized dermatological management. We suggest
that DD should be performed in these patients at 1, 2, and 3
months of treatment; then, a trimonthly follow-up could be
offered.
MATERIALS AND METHODS
Study design
All patients with previously untreated or refractory to standard therapy
metastatic or advanced melanoma harboring a V600 mutation, who
received the BRAF inhibitor vemurafenib recruited, treated, and
followed in a single melanoma center were unselectively consecu-
tively and prospectively included. The initial dosing regimen of
vemurafenib was at 960 mg twice daily. In accordance with current
guidelines, dose was reduced or treatment interrupted in the case of
grade 3 or intolerable grade 2 toxic effects. Therapy was discontinued
in the case of disease progression or severe adverse event. All patients
underwent full-body skin examination before starting therapy, and
there was no evidence of early melanoma. Dermatologic past-history
was also recorded (Fitzpatrick’s skin type, existence of an atypical
mole syndrome, familial past-history of melanoma, past-history of
intense sun-exposure). Every patient gave their informed consent for
prospective digital dermoscopic follow-up while under vemurafenib,
and signed an ethical committee-approved informed consent for
molecular testing on skin samples, if needed. Heine Delta 20 dermo-
scope (Heine, Herrsching, Germany), Dermlite Foto System (3gen,
San Juan Capistrano, CA) and Fotofinder dermoscope HD (FotoFinder
Systems, Bad Birnbach, Germany) were used during examination
to capture high-quality dermoscopic images. The first digital
Table 2. Percentage of changes observed in excised lesion and pathology result
Final diagnosis/
observed changes
Size
increase
Size
decrease
Darkening
of color
Enlightenment
of color
New dark
areas
Island of
regression
Island of atypical
network
New aggregated
globules
Atypical nevus 38% 0% 67% 19% 24% 19% 38% 52%
Second primary
melanoma
21% 7% 57% 7% 7% 14% 14% 36%
Lentigo 0% 0% 0% 0% 0% 0% 100% 0%
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dermoscopic recording was performed during pre-treatment total
body skin exam, and repeated monthly, until treatment discontinua-
tion. Dermoscopical evolution of the lesions was independently
classified by two of us (MP-M and SD) on the basis of 10 dermoscopic
criteria: size, intensity of pigmentation, localized color change,
appearance or disappearance of dots, change in network, occurrence
of dark structureless areas, appearance of superficial keratosis, pattern
changes, symmetry of the lesion, and vessel changes. The nine first
cases of melanomas observed in our center and included in this work
have been previously reported in collaborative works (Kong et al.,
2008; Huang et al., 2012; Kim et al., 2013).
Statistical analyses
All data have been sorted by SPSS program (IBM SPSS Statistics,
Armonk, NY), globally, for every month and for each criterion, to
compare percentage of modified lesions and stable lesions. Analyses
were realized for each single patient to determine the occurrence of
changing lesions, in one given patient. We then sub-classified the
patients into three groups depending on the frequency of observed
changes: group 1 with few changes (o40% of lesions modified),
group 2 with mild-to-moderate changes (40–59.9%), and group 3
with marked changes (60% or more). w2 Test has been used to
compare these three groups according to sex, Fitzpatrick’s skin type,
presence of atypical mole syndrome, important chronic sun-exposure,
and familial past-history of melanoma. Analysis of variance test has
been used to compare these three groups according to age. Finally,
dermoscopic features of modified-but-not-excised lesions (then con-
sidered to exhibit insignificant change(s)) and modified-and-excised
lesions (considered as exhibiting possible malignancy-induced
changes) during the first 6 months of follow-up were compared,
using w2 and Fisher’s exact test.
Dermatopathology and molecular studies
All lesions considered as potentially malignant on the basis of their
dermoscopical features or more importantly on the basis of their DD
recorded changes over time have been surgically excised to undergo
pathologic examination. All patients gave informed written consent
for the use of tissue samples for research purposes and genotype
analyses in accordance to the Declaration of Helsinki guidelines.
Tissue samples have been embedded in paraffin, and histology with
hematoxylin and eosin staining, and immunohistochemistry staining
for melan-A and HMB-45 have been performed. Diagnosis of primary
melanoma has been assessed by at least two independent dermato-
pathologists and the 10 first cases have been submitted to external
dermatopathology expert review, as described in previously pub-
lished work (Dalle et al., 2011, 2013). For mutation analysis, tumor
cells were microdissected using a Leica LMD 2000 (Wetzlar,
Germany). DNA was extracted, BRAF exon 15, and N-RAS exon 3
were PCR amplified and sequenced. Big dye terminator v1.3 kit and
ABI prism 3100 genetic analyzer (Applied Biosystems, Foster City,
CA) were used. Sense and antisense sequences were completed on
two independent PCR products.
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